94
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Circulating syndecan-1 as a novel biomarker relates to lung function, systemic inflammation, and exacerbation in COPD

, , , , , , , , , , , & show all
Pages 1933-1941 | Published online: 28 Aug 2019

References

  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
  • Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–799. doi:10.1016/S0140-6736(07)61383-X17765529
  • Ferrari R, Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14:24. doi:10.1186/1465-9921-14-1923425215
  • Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol. 2016;52(3):138–144. doi:10.1016/j.arbres.2015.01.01126002550
  • Hogg JC. A pathologist’s view of airway obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(5):v–vii. doi:10.1164/rccm.201206-1130ED22942353
  • Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med. 2011;105(Suppl 1):S31–S37. doi:10.1016/S0954-6111(11)70008-722015083
  • Conti V, Corbi G, Manzo V, et al. SIRT1 activity in peripheral blood mononuclear cells correlates with altered lung function in patients with chronic obstructive pulmonary disease. Oxid Med Cell Longev. 2018;2018:9391261. doi:10.1155/2018/939126129861836
  • Kufareva I. Chemokines and their receptors: insights from molecular modeling and crystallography. Curr Opin Pharmacol. 2016;30:27–37. doi:10.1016/j.coph.2016.07.00627459124
  • Agere SA, Kim EY, Akhtar N, Ahmed S. Syndecans in chronic inflammatory and autoimmune diseases: pathological insights and therapeutic opportunities. J Cell Physiol. 2018;233(9):6346–6358. doi:10.1002/jcp.2638829226950
  • Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111(5):635–646. doi:10.1016/s0092-8674(02)01079-612464176
  • Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by pseudomonas aeruginosa enhances virulence. Nature. 2001;411(6833):98–102. doi:10.1038/3507510011333985
  • Luo L, Feng S, Wu Y, Su Y, Jing F, Yi Q. Serum levels of syndecan-1 in patients with kawasaki disease. Pediatr Infect Dis J. 2019;38(1):89–94. doi:10.1097/INF.0000000000002047.
  • Santoso A, Kikuchi T, Tode N, et al. Syndecan 4 mediates Nrf2-dependent expansion of bronchiolar progenitors that protect against lung inflammation. Mol Ther. 2016;24(1):41–52. doi:10.1038/mt.2015.15326307669
  • Lee KS, Kim HR, Kwak S, et al. Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Ann Lab Med. 2013;33(1):45–51. doi:10.3343/alm.2013.33.1.4523301222
  • Sanchez-Pedrosa G, Vara Ameigeiras E, Casanova Barea J, Rancan L, Simon Adiego CM, Garutti Martinez I. Role of surgical manipulation in lung inflammatory response in a model of lung resection surgery. Interact Cardiovasc Thorac Surg. 2018;27:870–877. doi:10.1093/icvts/ivy19829945217
  • Lu Z, Song N, Shen B, et al. Syndecan-1 shedding inhibition to protect against ischemic acute kidney injury through HGF target signaling pathway. Transplantation. 2018;102(7):e331–e344. doi:10.1097/TP.000000000000217029557914
  • Xu J, Park PW, Kheradmand F, Corry DB. Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol. 2005;174(9):5758–5765. doi:10.4049/jimmunol.174.9.575815843578
  • Brauer R, Ge L, Schlesinger SY, et al. Syndecan-1 attenuates lung injury during influenza infection by potentiating c-Met signaling to suppress epithelial apoptosis. Am J Respir Crit Care Med. 2016;194(3):333–344. doi:10.1164/rccm.201509-1878OC26959387
  • Lam DC, Chan SC, Mak JC, Freeman C, Ip MS, Shum DK. S-maltoheptaose targets syndecan-bound effectors to reduce smoking-related neutrophilic inflammation. Sci Rep. 2015;5:12945. doi:10.1038/srep1294526256047
  • Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–1238. doi:10.1183/09031936.0010990617540785
  • Chen YW, Leung JM, Sin DD. A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS One. 2016;11(7):e0158843. doi:10.1371/journal.pone.015884327434033
  • Crisafulli E, Torres A, Huerta A, et al. C-reactive protein at discharge, diabetes mellitus and >/=1 hospitalization during previous year predict early readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. COPD. 2015;12(3):306–314. doi:10.3109/15412555.2014.93395425279441
  • Rautava J, Soukka T, Heikinheimo K, Miettinen PJ, Happonen RP, Jaakkola P. Different mechanisms of syndecan-1 activation through a fibroblast-growth-factor-inducible response element (FiRE) in mucosal and cutaneous wounds. J Dent Res. 2003;82(5):382–387. doi:10.1177/15440591030820051112709506
  • Vered M, Dayan D, Yahalom R, et al. Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int J Cancer. 2010;127(6):1356–1362. doi:10.1002/ijc.2535820340130
  • Mahmood MQ, Walters EH, Shukla SD, et al. beta-catenin, twist and snail: transcriptional regulation of EMT in smokers and COPD, and relation to airflow obstruction. Sci Rep. 2017;7(1):10832. doi:10.1038/s41598-017-11375-x28883453